Cell-Specific Targeting LNP Made Simple

A standard approach to assess targeted lipid nanoparticle (LNP) delivery is to encapsulate GFP mRNA and compare GFP expression in the presence or absence of the targeting ligand.

The recent publication of the first in vivo CAR-T clinical study for SLE is a major milestone. This new targeted LNP platform offers huge potential— patient accessibility, scalability, speed, and cost-efficiency—but how does it measure up to ex vivo approaches?